<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Psychiatry Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J Psychiatry Neurosci</journal-id>
<journal-title-group>
<journal-title>Journal of Psychiatry &amp; Neuroscience : JPN</journal-title>
</journal-title-group>
<issn pub-type="ppub">1180-4882</issn>
<issn pub-type="epub">1488-2434</issn>
<publisher>
<publisher-name>Joule Inc.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28234206</article-id>
<article-id pub-id-type="pmc">5403662</article-id>
<article-id pub-id-type="doi">10.1503/jpn.150332</article-id>
<article-id pub-id-type="publisher-id">jpn-42-172</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Bipolar disorder risk gene <italic>FOXO6</italic> modulates negative symptoms in schizophrenia: a neuroimaging genetics study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shenker</surname>
<given-names>Joseph J.</given-names>
</name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sengupta</surname>
<given-names>Sarojini M.</given-names>
</name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Joober</surname>
<given-names>Ridha</given-names>
</name>
<degrees>MD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malla</surname>
<given-names>Ashok</given-names>
</name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chakravarty</surname>
<given-names>M. Mallar</given-names>
</name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lepage</surname>
<given-names>Martin</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="corresp" rid="c1-jpn-42-172"></xref>
</contrib>
<aff id="af1-jpn-42-172">From the Douglas Mental Health University Institute, Montreal, Que., Canada (Shenker, Sengupta, Joober, Malla, Chakravarty, Lepage); the Integrated Program in Neuroscience, McGill University, Montreal, Que., Canada (Shenker, Lepage); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Sengupta, Joober, Malla, Chakravarty, Lepage); and the Department of Biomedical Engineering, McGill University, Montreal, Que., Canada (Chakravarty)</aff>
</contrib-group>
<author-notes>
<corresp id="c1-jpn-42-172">Correspondence to: M. Lepage, Douglas Mental Health University Institute, Frank B Common Pavilion, F1143, 6875 LaSalle Blvd, Verdun, Quebec, Canada H4H 1R3; <email>martin.lepage@mcgill.ca</email></corresp>
<fn fn-type="COI-statement" id="fn1-jpn-42-172">
<p><bold>Competing interests:</bold> See jpn.ca/about for R. Joober. M. Lepage reports grants and personal fees from Otsuka Canada, Lundbeck and Janssen-Ortho, outside the submitted work. No other competing interests declared.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>42</volume>
<issue>3</issue>
<fpage>172</fpage>
<lpage>180</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>20</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>8</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 Joule Inc.</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Despite being diagnostically associated uniquely with schizophrenia, negative symptoms are also observed in bipolar disorder (BD). Genome-wide association studies (GWAS) have uncovered a number of shared risk genes between schizophrenia and BD. The objectives of this study were to examine whether previously identified risk genes for BD are associated with negative symptom severity within a first-episode schizophrenia (FES) cohort and to examine whether such genes influence brain morphology.</p>
</sec>
<sec>
<title>Methods</title>
<p>Patients experiencing FES were genotyped for 21 previously identified BD risk genes; a series of univariate analyses of covariance examined the association between negative symptom severity, as measured using the Scale for the Assessment of Negative Symptoms (SANS), and genotype. A subset of participants underwent a structural 1.5 T MRI <italic>T</italic><sub>1</sub> scan, analyzed for surface area and cortical thickness changes via the CIVET pipeline and LPBA40 atlas.</p>
</sec>
<sec>
<title>Results</title>
<p>We included 133 patients with FES in our analysis; 61 of them underwent structural MRI. We observed a significant association between negative symptom severity and the BD risk gene <italic>FOXO6</italic> (rs4660531). Individuals with the CC genotype presented significantly higher negative symptoms (Cohen <italic>d</italic> = 0.46, <italic>F</italic> = 5.854, <italic>p</italic> = 0.017) and significantly smaller surface area within the right middle orbitofrontal gyrus (Cohen <italic>d</italic> = 0.69, <italic>F</italic> = 7.289, <italic>p</italic> = 0.009) than carriers of allele A.</p>
</sec>
<sec>
<title>Limitations</title>
<p>Limitations of this study include its modest sample size and lack of a control sample.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Lacking the <italic>FOXO6</italic> risk allele was associated with an increase in negative symptoms and surface area reduction in the right orbitofrontal gyrus — an area previously associated with negative symptoms —– suggesting that presence of the <italic>FOXO6</italic> risk allele confers resistance against negative symptoms and associated neuroanatomical changes in individuals with FES.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>